Texas Biomedical Research Institute

Trinity University Receives Largest Gift in the University’s History for Naming of the D. R. Semmes School of Science

Retrieved on: 
Friday, March 8, 2024
Physics, Trinity University, Computer science, Research, Education, DoorDash, STEM, Mentorship, Molecular biology, Learning, Astronomy, Texas Biomedical Research Institute, Biochemistry, Faculty, University, School, History, Human, Council, Support, Southwest Research Institute, Microsoft, Advancement, Software, Student, Management

San Antonio, March 08, 2024 (GLOBE NEWSWIRE) -- With the largest gift in Trinity University’s history at $26.5 million, the University is honored to announce the naming of the D. R. Semmes School of Science .

Key Points: 
  • San Antonio, March 08, 2024 (GLOBE NEWSWIRE) -- With the largest gift in Trinity University’s history at $26.5 million, the University is honored to announce the naming of the D. R. Semmes School of Science .
  • “This investment by the Semmes Foundation accelerates our goal to deliver the best undergraduate science education in the United States,” said Vanessa B. Beasley, Ph.D., President of Trinity University.
  • “The sciences are at the core of a broad liberal arts education, and Trinity fundamentally understands this.
  • “We look forward to collaborating with Trinity and offering its students real-world experience in the sciences.”
    The history between the Semmes Foundation and Trinity University runs deep.

Cancer therapy shows promise against tuberculosis

Retrieved on: 
Thursday, November 16, 2023
Texas Biomedical Research Institute, Apoptosis, Granuloma, Research, SAN, Immune system, Miliary tuberculosis, Protein, Macrophage, Mouse, Patient, Multimedia, Biomedicine & Pharmacotherapy, FDA, Death, Vaccine, Immunotherapy, Infection, Neoplasm, Drug resistance, Bacteria, Cancer, Human, Doctor of Philosophy, Growth, Volunteering, Cell, Tuberculosis, TB, Pharmaceutical industry, MD

SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).

Key Points: 
  • SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).
  • - Larry Schlesinger, MD
    Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant.
  • The therapy evaluated in this study combines two molecules – one is already FDA-approved for cancer patients, and the other is in Phase 1/2 clinical trials for cancer.
  • That's the power of a host-directed therapy targeting the human's immune response versus trying to attack the pathogen directly."

American Lung Association Invests in Critical Work to Create Universal Flu Shot

Retrieved on: 
Wednesday, October 4, 2023
Partnership, American Lung Association, Texas Biomedical Research Institute, Disbursement Acceleration Program, Research, Doctor of Philosophy, Canadian Lung Association, Government, CDC, Death, Influenza, Korea Disease Control and Prevention Agency, Pharmaceutical industry, Vaccine

CHICAGO, Oct. 4, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced a three-year, $500,000 grant to Texas Biomedical Research Institute to help accelerate its efforts to develop a universal flu vaccine. This is the first Accelerator Program investment that the Lung Association has made since it launched the American Lung Association Research Institute earlier this year.

Key Points: 
  • CHICAGO, Oct. 4, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced a three-year, $500,000 grant to Texas Biomedical Research Institute to help accelerate its efforts to develop a universal flu vaccine.
  • This is the first Accelerator Program investment that the Lung Association has made since it launched the American Lung Association Research Institute earlier this year.
  • "This partnership with the American Lung Association enables us to move quickly with this vaccine research."
  • This funding was provided by the American Lung Association Research Institute, which launched in March to address the urgent and critical lung health challenges in our country.

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Tuesday, August 8, 2023
GMP, Travel, IV, Senior, Shield, Telephone, Survival, Head, Teaching hospital, Congress, Biomedical Research Institute, Acquisition, Patient, NYSE, Texas Biomedical Research Institute, VCN, Brain, University, Therapy, Cancer, Immunotherapy, Coronavirus Scientific Advisory Board, Research, University of Pennsylvania, FDA, Safety, Pancreatic cancer, ESMO, ICO, HCT, CAR, Ovarian cancer, ST, Clinical trial, Neck, ET, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical imaging, Cryptocurrency, PDAC, Discovery, U.S

ET -

Key Points: 
  • ET -
    ROCKVILLE, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
  • These results build on the impressive safety, biochemical and mechanistic data presented last year, demonstrating that VCN-01 improved tumor immunogenicity in previously immunotherapy refractory patients.
  • Second Quarter Ended June 30, 2023 Financial Results
    General and administrative expenses increased to $2.7 million for the three months ended June 30, 2023, from $1.5 million for the three months ended June 30, 2022.
  • ET to discuss its financial results for the quarter ended June 30, 2023 and provide a corporate update.

Health equity at heart of Texas Biomed's 3rd Global Health Symposium

Retrieved on: 
Monday, April 24, 2023
Business development, Senior, San Antonio Botanical Garden, Health care, National Science Foundation, Policy, Roche, COVID-19, United States Agency for International Development, Health equity, Infection, Peace Corps, Business, Biomedical Research, Hope, Viasat, Research, Multimedia, Henrietta Lacks, Texas Biomedical Research Institute, Equity, Bangladesh Technical Education Board, International development, Movement, Science, Organization, Global Health, Student, Trust, HeLa, Cervical cancer, Grassroot Soccer, SAN, Pandemic, American Standard Companies, Sanofi, Bill, CDT, MPH, USAID, San Antonio, Management, MD, Data

SAN ANTONIO, April 24, 2023 /PRNewswire/ -- Texas Biomedical Research Institute's 3rd Global Health Symposium on May 18 and 19 will convene experts from across the nation and the world to discuss how community, trust and science can help build health equity.

Key Points: 
  • SAN ANTONIO, April 24, 2023 /PRNewswire/ -- Texas Biomedical Research Institute's 3rd Global Health Symposium on May 18 and 19 will convene experts from across the nation and the world to discuss how community, trust and science can help build health equity.
  • More than 60 global health executives, healthcare providers, philanthropists, business leaders, scientists, educators and students will be featured during 12 panel sessions and three keynote addresses.
  • "But to truly achieve that, we must bring together innovators from across many different sectors and global communities to collaborate and build health equity."
  • Decolonizing Global Health: What should be the target of this movement and where does it lead us?

Deadly Candida Auris Fungus Outbreak -- Xenex LightStrike UV Robot Proven to Kill Superbug in Hospitals

Retrieved on: 
Monday, March 27, 2023
Other Health, Other Science, Research, Other Technology, Medical Devices, Building Systems, Infectious Diseases, Hardware, Hospitals, Science, Technology, Construction & Property, Medical Supplies, Managed Care, General Health, Biotechnology, Health, Robotics, Health Technology, Clostridioides, SARS-CoV-2, Methicillin-resistant Staphylococcus aureus, Hospital, Yale School of Medicine, COVID-19, MRSA, Texas Biomedical Research Institute, Cell wall, Veteran, Prison, Acinetobacter, CDC, San Antonio Spurs, Clostridioides difficile, School, Patient, UV, Korea Disease Control and Prevention Agency, Veterans' affairs, Bacteria, System, Anthrax, Mackenzie Calhoun, Spore, Auris, Vaccine, Sewage treatment, Pharmaceutical industry

Hospitals worldwide report they are unable to combat the outbreak of the deadly Candida auris fungus with traditional disinfectants.

Key Points: 
  • Hospitals worldwide report they are unable to combat the outbreak of the deadly Candida auris fungus with traditional disinfectants.
  • View the full release here: https://www.businesswire.com/news/home/20230327005447/en/
    Xenex LightStrike robots are proven to destroy Candida auris, the deadly fungus spreading in U.S. healthcare facilities.
  • (Photo: Business Wire)
    However, hospitals using Xenex Disinfection Services’ LightStrike UV room disinfection robot have reported success battling the fungus, which is contaminating medical facilities and killing patients.
  • There are thousands of Xenex LightStrike robots deployed at more than 1,000 hospitals on five continents and across the U.S.

Texas Biomed at forefront of Sudan ebolavirus biomedical R&D

Retrieved on: 
Monday, December 19, 2022
Office of Inspector General, U.S. Department of Health and Human Services, World Health Organization, Biomedical Advanced Research and Development Authority, Patient, Business development, BARDA, SAN, Administration, U.S. Department of Defense Strategy for Operating in Cyberspace, Southwest National Primate Research Center, BSL-4, Texas Biomedical Research Institute, FDA, Safety, Multimedia, Government, Infection, Vaccine, Doctor of Philosophy, Development, Research, Sabin Vaccine Institute, Pharmaceutical industry

A vaccine and therapeutic tested at Texas Biomed have been sent to Uganda to help control the Sudan ebolavirus outbreak.

Key Points: 
  • A vaccine and therapeutic tested at Texas Biomed have been sent to Uganda to help control the Sudan ebolavirus outbreak.
  • Sudan ebolavirus is one of six known Ebola species, with a fatality rate ranging between 41% and 100%.
  • Texas Biomed will continue to help advance vaccines and therapies for Sudan ebolavirus.
  • Through basic research, preclinical testing and innovative partnerships, Texas Biomed accelerates diagnostics, therapies and vaccines for the world's deadliest pathogens.

Texas Biomedical Research Institute in San Antonio Added to National Readiness and Preparedness Network

Retrieved on: 
Tuesday, December 13, 2022
Laboratory, Bioterrorism, United States Department of Health and Human Services, State, Infection, Development, Biomedical Advanced Research and Development Authority, Human services, Partnership, ASPR, IDIQ, Pandemic, Research, Texas Biomedical Research Institute, Office of Inspector General, U.S. Department of Health and Human Services, Southwest National Primate Research Center, BARDA, Sabin Vaccine Institute, DHHS, COVID-19, Administration, Human, Vaccine, National Primate Research Center, Federal, SAN, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharmaceutical industry

SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- The federal agency that protects against pandemics and bioterrorism has elevated Texas Biomedical Research Institute into the top ranks of its national readiness and preparedness network.

Key Points: 
  • SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- The federal agency that protects against pandemics and bioterrorism has elevated Texas Biomedical Research Institute into the top ranks of its national readiness and preparedness network.
  • "This is a huge win for San Antonio and Texas Biomed not to mention for the whole state," said State Sen. Jose Menendez, D-San Antonio.
  • Texas Biomed is the nation's only non-profit, independent research institute with the highest-level biocontainment laboratories, a national primate research center and over 80 years of experience.
  • Our San Antonio campus hosts high containment laboratories and the Southwest National Primate Research Center.

SNU Bundang Hospital and Cipherome, Inc. conclude an MOU for cooperation in Personalized Medicine

Retrieved on: 
Wednesday, November 16, 2022
Software, Research, Pharmaceutical, Technology, Hospitals, Genetics, Artificial Intelligence, Health Technology, Science, Cardiology, Biotechnology, Health, Other Science, Bridge, Genomics, AI, Moyamoya disease, Biobank, Drug development, Machine learning, Multimedia, Precision medicine, Biomedical Research Institute, MOU, Medicine, UK Biobank, Research, Seoul National University, Seoul National University Bundang Hospital, UK, ADR, National university, Diabetes, SNU, Texas Biomedical Research Institute, Silicon, Data analysis, Patient, Medical device

Seoul National University (SNU) Bundang Hospital Biomedical Research Institute announced that it concluded the MOU on November 15, 2022, to standardize clinico genomic research using Cipherome, Inc.s precision medicine research platform at Precision Medicine Center.

Key Points: 
  • Seoul National University (SNU) Bundang Hospital Biomedical Research Institute announced that it concluded the MOU on November 15, 2022, to standardize clinico genomic research using Cipherome, Inc.s precision medicine research platform at Precision Medicine Center.
  • View the full release here: https://www.businesswire.com/news/home/20221116006039/en/
    Seoul National University Bundang Hospital Biomedical Research Institute signed a memorandum of understanding (MOU) with Cipherome, Inc., a precision medicine bio venture company based in Silicon Valley, USA, to build a precision medicine research platform.
  • Ji-Soo Kim, the president of Seoul National University Bundang Hospital Biomedical Research Institute, stated: Through this MOU with Cipherome, we will actively support the precision medicine R&D based on clinical and genomic big data.
  • We hope that this MOU will contribute to improving the precision medicine research competitiveness and capability of Seoul National University Bundang Hospital.

Modified bladder cancer treatment shows promise in animal studies

Retrieved on: 
Tuesday, August 23, 2022
Inflammation, Patient, Cancer, Lipid, Research, Bladder cancer, SAN, Death, Doctor of Philosophy, Disease, Man, BCG, Texas Biomedical Research Institute, Southwest Research Institute, University of Texas Health Science Center at San Antonio, Quality of life, American Cancer Society, Cell, Cancer immunology, BCG vaccine, MD, FDA, Tuberculosis, Clinical trial, Woman, Industry, Drug development, UT Health San Antonio Cancer Center, Bacteria, Dietary supplement, Pharmaceutical industry, Vaccine, Medical device, Immunotherapy, TB, Mycobacterium

SAN ANTONIO, Aug. 23, 2022 /PRNewswire/ -- A modified tuberculosis vaccine developed at Texas Biomedical Research Institute could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects.

Key Points: 
  • SAN ANTONIO, Aug. 23, 2022 /PRNewswire/ -- A modified tuberculosis vaccine developed at Texas Biomedical Research Institute could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects.
  • A modified TB vaccine developed at Texas Biomed could help treat a type of bladder cancer without strong side effects.
  • About 75% of bladder cancer cases are classified as non-muscle invasive, which means the cancer affects the tissue lining the inner surface of the bladder, but not the bladder muscle.
  • Dr. Svatek's lab conducted the tests in a mouse model of bladder cancer and in cells collected from human cancer patients.